Adrenomed’s goal is to fill the gap in patient treatment further downstream of inflammation with Adrecizumab, the first sepsis therapy candidate to target an important causal pathophysiology of ...

Inflammation and coagulation are closely linked in sepsis. Inflammatory mediators generate tissue factor expression and initiate coagulation through activation of the extrinsic pathway ...